United States Drug Patent 8,183,295: Claim Scope, Exclusivity, Litigation, and Competitive Patent Landscape

US Patent 8,183,295 protects pharmaceutical compositions combining aliskiren, amlodipine, and hydrochlorothiazide in specified dosage ranges. The patent is directed to a fixed or unit-dose triple antihypertensive combination with a claimed therapeutic effect greater than the effects achieved by the individual components administered alone. Its commercial relevance centered on Novartis’s Amturnide product, which combined the same three active ingredients.

The patent does not protect aliskiren, amlodipine, or hydrochlorothiazide individually. Those active ingredients have separate historical patent estates, but the principal inventive position in US 8,183,295 is the triple combination and its dosage architecture.

What does US Patent 8,183,295 protect?

The patent claims a composition containing all three active ingredients:

Component	Independent claim 1 range	Narrower ranges in dependent claims
Aliskiren or pharmaceutically acceptable salt	150-500 mg	140-220 mg in claim 6; 550-700 mg in claim 7
Amlodipine or pharmaceutically acceptable salt	1.0-40 mg	2.5-25 mg in claims 2-4; 2.0-12 mg in claims 6-7
Hydrochlorothiazide	5-200 mg	5-25 mg in claims 3-4; 5-15 mg in claim 6; 5-30 mg in claim 7
Pharmaceutical carrier	One or more carriers	Required in every claim
Therapeutic relationship	Greater effect than the components administered alone	Required in every claim

Claims 1-4 are composition claims. Claims 5-7 add a unit-dose requirement and provide narrower or alternative dose bands.

The word "consisting of" narrows the claimed composition. It generally excludes additional active pharmaceutical ingredients that materially alter the claimed composition, although pharmaceutical carriers and excipients remain permitted because the claims expressly include them.

How do claims 1 through 7 differ?

Claim 1: Broad triple-combination composition

Claim 1 covers a composition containing:

150-500 mg aliskiren;
1.0-40 mg amlodipine;
5-200 mg hydrochlorothiazide; and
one or more pharmaceutically acceptable carriers.

The claim also requires that the combination achieve a greater therapeutic effect than the corresponding ingredients administered alone.

Claim 1 is the principal broad composition claim. It covers a wide dose matrix, including many clinically conventional antihypertensive strengths.

Claims 2 through 4: Narrower amlodipine and hydrochlorothiazide ranges

Claim 2 narrows amlodipine to 2.5-25 mg.

Claim 3 depends on claim 2 and narrows hydrochlorothiazide to 5-25 mg.

Claim 4 independently narrows hydrochlorothiazide to 5-25 mg while retaining claim 1’s broader amlodipine range of 1.0-40 mg.

The practical hierarchy is:

Claim	Aliskiren	Amlodipine	Hydrochlorothiazide	Unit dose required?
1	150-500 mg	1.0-40 mg	5-200 mg	No express unit-dose requirement
2	150-500 mg	2.5-25 mg	5-200 mg	No
3	150-500 mg	2.5-25 mg	5-25 mg	No
4	150-500 mg	1.0-40 mg	5-25 mg	No

Claim 5: Unit-dose version of the broad composition

Claim 5 repeats the broad ingredient ranges in claim 1 but requires that the three components be administered in a unit dosage form.

A single tablet, capsule, or other dosage unit containing the three active ingredients would fall within the core factual pattern of claim 5 if the therapeutic-effect limitation is satisfied.

Claim 6: Lower-dose unit combination

Claim 6 covers a unit dose containing:

140-220 mg aliskiren;
2.0-12 mg amlodipine; and
5-15 mg hydrochlorothiazide.

This claim is narrower by dosage range but commercially important because it covers lower-strength fixed-dose combinations. It may also cover a product using an aliskiren salt, provided the relevant amount is measured consistently with the claim and product labeling.

Claim 7: Higher-dose aliskiren unit combination

Claim 7 covers:

550-700 mg aliskiren;
2.0-12 mg amlodipine; and
5-30 mg hydrochlorothiazide.

This is an alternative high-aliskiren dosage profile. It should not be treated as a simple extension of claim 6 because the aliskiren range is materially different. A product containing 300 mg aliskiren per tablet would not literally satisfy the 550-700 mg limitation of claim 7, although other claims may remain relevant depending on the total composition and administration protocol.

What is the key legal limitation in US 8,183,295?

The key functional limitation is the requirement that the triple combination achieve a "greater therapeutic effect" than the corresponding amounts administered alone.

This limitation creates both value and litigation risk.

The claim is not drafted solely around the presence and amount of three active ingredients. It also requires a comparative therapeutic result. The patent specification and prosecution record would be central to determining:

what "greater therapeutic effect" means;
whether the comparison is against each component individually or against other combinations;
whether the effect must be synergistic rather than merely additive;
what disease endpoint is measured;
what patient population is relevant;
whether the comparison must use the same doses;
whether clinical data, animal data, or in vitro evidence is sufficient.

The claim language appears to require a combination effect exceeding the effect of the individual ingredients administered alone. It does not expressly state a numerical synergy threshold. That omission may create claim-construction disputes in an infringement action.

A generic product may contain the claimed ingredients and dose ranges but contest infringement by arguing that the therapeutic-effect limitation is not met. The patent holder could respond using the product label, clinical studies, pharmacodynamic data, or testing of the accused formulation.

What formulations are protected by the patent?

The patent protects compositions containing all three active ingredients with at least one pharmaceutically acceptable carrier. The claims do not require a particular excipient, tablet coating, release profile, particle size, crystalline form, or manufacturing process.

Potentially covered dosage forms include:

immediate-release tablets;
capsules;
multiparticulate oral dosage forms;
granules or powders intended for oral administration;
other unit-dose pharmaceutical compositions containing the three actives.

The claims do not expressly require that the three ingredients be physically combined in one tablet. Claims 1-4 are composition claims without an express unit-dose limitation. Claims 5-7 expressly require administration in a unit dosage form.

This distinction matters for product design. A coordinated regimen using three separate tablets may raise a different claim analysis from a single fixed-dose tablet. Claims 5-7 are more directly oriented toward a unit-dose product, while claims 1-4 may reach a broader composition or administration package depending on claim construction and the patent’s specification.

Does US 8,183,295 protect a method of treatment?

The issued claims supplied are composition claims, not conventional method-of-treatment claims. They do not expressly recite:

treating hypertension;
administering the composition to a patient;
reducing blood pressure;
preventing cardiovascular events; or
treating a named patient population.

The therapeutic-effect language operates as a limitation on the claimed composition. It does not convert the claims into conventional treatment-method claims.

The patent therefore presents a composition-focused barrier. A competing product may need to address the ingredient ranges, unit-dose requirements, and comparative-effect limitation rather than only a method-of-use restriction.

When does US 8,183,295 lose exclusivity?

US 8,183,295 issued on May 22, 2012. The patent claims priority to an earlier 2006 filing, with the relevant US patent term generally calculated from the applicable nonprovisional or international filing date rather than the earliest priority date. Public patent records identify a nominal expiration in April 2027, subject to any patent-term adjustment or other term calculation reflected in the official record.[1]

Event	Date
Earliest claimed priority	2006
Patent issued	May 22, 2012
Nominal patent-term endpoint	April 2027
Post-expiration position	Generic or authorized-generic entry is no longer blocked by this patent alone

The patent does not create a permanent barrier to generic entry. The commercial exclusivity analysis must also account for:

other aliskiren patents;
product-specific formulation patents;
Orange Book-listed patents for the relevant NDA;
regulatory exclusivity;
pediatric exclusivity;
patent-term adjustment;
litigation settlements; and
non-patent commercial barriers.

What is the FDA and Orange Book status of the related product?

The relevant commercial product was Amturnide, a fixed-dose combination of aliskiren, amlodipine, and hydrochlorothiazide marketed by Novartis. FDA approved Amturnide in 2010 for hypertension.[2]

The product was associated with the aliskiren-containing product family, including Tekturna and Valturna. FDA later required changes to aliskiren labeling after safety findings involving use with renin-angiotensin system blockers in patients with diabetes or renal impairment. Novartis discontinued Amturnide and certain related aliskiren combinations for commercial reasons after the ALTITUDE safety findings and declining market demand.[3]

Discontinuation does not itself invalidate a patent. A patent can remain enforceable after a product is withdrawn, although the commercial value of the patent may decline sharply.

The Orange Book question is product-specific. A patent may be listed against an NDA only if it meets FDA listing requirements and is submitted for the approved drug. The relevant analysis should distinguish:

whether US 8,183,295 was listed for Amturnide;
whether that listing remained active;
whether the NDA was withdrawn or discontinued;
whether an ANDA applicant received a Paragraph IV notice; and
whether the patent was still unexpired when the ANDA litigation window opened.

The patent itself does not establish Orange Book listing status. That status must be confirmed through FDA’s current Orange Book data and historical listing records.[4]

Are there Paragraph IV challenges or patent litigation?

A Paragraph IV challenge would be the principal Hatch-Waxman pathway for an ANDA applicant seeking to market a generic triple-combination product before the patent’s expiration.

The applicant could assert that:

the patent is invalid;
the patent is unenforceable;
the proposed product does not infringe;
the therapeutic-effect limitation is not met;
the product does not satisfy the unit-dose limitation;
one or more active ingredients fall outside the claimed ranges; or
the patent is not properly listed for the relevant reference product.

A Paragraph IV notice could trigger a 45-day period for the patent holder to file an infringement action. A timely action generally results in a 30-month stay of FDA approval, subject to statutory exceptions and court developments.[5]

The supplied record does not establish a specific reported district-court judgment, Federal Circuit decision, or publicly documented settlement involving US 8,183,295. The absence of a known reported decision means the patent’s practical strength is determined primarily by claim construction, prosecution history, written-description support, enablement, and the product-specific evidence concerning therapeutic effect.

How strong is the patent estate for the triple combination?

The patent estate is narrower than a basic active-ingredient patent but potentially strong against a direct fixed-dose copy.

Strengths

The claims cover the specific three-drug combination.
The dose ranges encompass clinically relevant strengths.
Claims 5-7 specifically address unit-dose administration.
The patent uses both broad and narrower fallback claim structures.
The three components act through different antihypertensive mechanisms, supporting a plausible combination rationale.

Weaknesses

Aliskiren, amlodipine, and hydrochlorothiazide are individually established compounds.
The inventive distinction depends heavily on the combination effect.
"Greater therapeutic effect" may require factual proof.
The claims do not identify a precise numerical threshold for the claimed effect.
A competitor may design around the dose ranges or use separate dosage units.
The commercial product associated with the patent was discontinued, reducing the immediate market incentive for a direct challenge.

The strongest infringement case would involve a single oral dosage form containing all three ingredients within the claimed ranges and marketed for the same hypertension population. The most vulnerable scenario would involve a product outside the dose ranges, separate administration units, or clinical evidence that does not satisfy the claimed comparative effect.

How does US 8,183,295 compare with the underlying drug patents?

Subject	Primary protection	Current strategic relevance
Aliskiren	Compound and pharmaceutical-use patents	Core compound patents are substantially older and generally expired or near expiration
Amlodipine	Compound and salt patents	Foundational protection has expired
Hydrochlorothiazide	Long-established diuretic	No meaningful modern compound exclusivity
Aliskiren/amlodipine/HCTZ	Combination patent, including US 8,183,295	Main historical protection for the triple product
Product formulation	May involve separate patents if specifically claimed	Requires separate Orange Book and family review
Manufacturing process	Potential process or salt/form patents	May affect API sourcing but does not automatically block finished-dose entry

The patent’s commercial value derives from combination coverage, not from exclusivity over any individual active ingredient.

What generic launch risks exist?

A generic applicant would likely evaluate four launch paths.

1. At-risk launch before nominal expiration

The applicant could file an ANDA with a Paragraph IV certification and launch before the patent expires after resolving litigation or prevailing in court. This carries damages and injunction risk.

2. Paragraph III filing

The applicant could certify that it will not market until the patent expires. This reduces litigation exposure but delays launch until the patent-term endpoint.

3. Dose-range design-around

A product could avoid literal infringement by using an active ingredient amount outside a claimed range. This approach must account for overlapping claims. For example, avoiding claim 6 does not necessarily avoid claim 1 or claim 5.

4. Separate-component strategy

A manufacturer could market separate aliskiren, amlodipine, and hydrochlorothiazide products rather than a single triple-combination product. This may reduce exposure to claims requiring a unit dosage form, but it does not automatically eliminate the risks associated with broader composition claims or inducement theories.

What biosimilar risk applies?

Biosimilar risk is not material for US 8,183,295. Aliskiren, amlodipine, and hydrochlorothiazide are chemically synthesized small-molecule drugs, not biologics regulated through the Biologics Price Competition and Innovation Act pathway.

A competing product would use the ANDA pathway, not a 351(k) biosimilar application. The relevant issues are bioequivalence, pharmaceutical equivalence, patent certification, Orange Book listing, and formulation comparability.[5]

What licensing deals affect the patent?

Novartis was the principal commercial sponsor associated with aliskiren products and Amturnide. A separate licensing arrangement would matter if ownership, prosecution, enforcement, or commercialization rights were transferred to another company.

The patent record and product history identify Novartis as the central rights holder and marketer for the relevant product family. No material third-party license is established by the claims themselves. A patent assignment, co-owner interest, or settlement license would need to be reviewed in the USPTO assignment database and court filings rather than inferred from the claim language.[1]

What is the geographic coverage?

US 8,183,295 provides rights only in the United States. The corresponding international patent family may include applications in Europe and other jurisdictions, but each national right has its own:

claim set;
expiration date;
prosecution history;
validity position;
supplementary protection certificate status;
Orange Book equivalent;
litigation record; and
regulatory linkage.

A freedom-to-operate review for Canada, Europe, Japan, China, or other markets cannot rely on the US claims alone. The most relevant international family members would be those claiming the same aliskiren/amlodipine/hydrochlorothiazide combination and dosage ranges.

Key Takeaways

US 8,183,295 covers triple pharmaceutical compositions containing aliskiren, amlodipine, and hydrochlorothiazide.
The broadest stated range is 150-500 mg aliskiren, 1.0-40 mg amlodipine, and 5-200 mg hydrochlorothiazide.
Claims 5-7 add unit-dose requirements and provide narrower dose combinations.
The therapeutic-effect limitation is central to both patent value and infringement risk.
The patent protects the combination, not the individual active ingredients.
The associated product was Amturnide, a Novartis fixed-dose antihypertensive combination.
The nominal patent-term endpoint is in April 2027, subject to the official term calculation.
Generic challenges would proceed through ANDA Paragraph IV or Paragraph III certifications, not the biosimilar pathway.
The strongest risk applies to a single unit-dose product containing all three ingredients within the claimed ranges.
Dose design-arounds and separate-component products may reduce, but do not automatically eliminate, infringement risk.
Product-specific Orange Book status, patent-term adjustment, assignments, litigation, and settlements must be assessed separately from the issued claims.

FAQs

Is a product containing 300 mg aliskiren, 10 mg amlodipine, and 25 mg hydrochlorothiazide automatically infringing?

No. Those amounts fall within several numerical ranges, but infringement also depends on the pharmaceutical composition, unit-dose structure, salt accounting, carrier limitations, and the claimed greater therapeutic effect.

Does using aliskiren hemifumarate avoid US 8,183,295?

Not necessarily. The claims expressly cover aliskiren and pharmaceutically acceptable salts. The relevant amount and whether it is measured as aliskiren free base or salt require analysis of the claim, specification, prosecution history, and product labeling.

Can a three-tablet regimen avoid the patent?

It may avoid claims that require administration in a unit dosage form, particularly claims 5-7. Claims 1-4 do not expressly contain the same unit-dose limitation, so a separate-tablet strategy requires claim-by-claim analysis.

Does discontinuation of Amturnide cancel the patent?

No. Product discontinuation does not terminate an issued patent. It can reduce the commercial value of the patent and affect the likelihood of future enforcement.

Can a generic manufacturer launch immediately after Amturnide discontinuation?

Not automatically. The manufacturer must evaluate the NDA’s regulatory status, Orange Book listings, remaining patent term, ANDA requirements, applicable certifications, and any other patents covering the product or its ingredients.

References

United States Patent and Trademark Office. (2012). US Patent No. 8,183,295, pharmaceutical compositions comprising aliskiren, amlodipine and hydrochlorothiazide.
U.S. Food and Drug Administration. (2010). Amturnide prescribing information. Novartis Pharmaceuticals Corporation.
U.S. Food and Drug Administration. (2012). FDA drug safety communication: New warnings and contraindications for blood pressure medicines containing aliskiren.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1507558	⤷ Start Trial	C300528	Netherlands	⤷ Start Trial
European Patent Office	1507558	⤷ Start Trial	CA 2012 00018	Denmark	⤷ Start Trial
European Patent Office	1507558	⤷ Start Trial	92000	Luxembourg	⤷ Start Trial
European Patent Office	1507558	⤷ Start Trial	2012/018	Ireland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,183,295

Summary for Patent: 8,183,295